Effects of Liposomal Encapsulation on Calcium Powder Absorption and Metabolism
1 other identifier
interventional
20
1 country
2
Brief Summary
Compared with traditional calcium supplements, liposome calcium can increase the bioavailability of calcium and reduce the waste caused by gastric acid destruction of calcium. This allows calcium to be released slowly in the intestines, reducing the risk of indigestion or other side effects caused by excessive intake at one time. Liposomal calcium can be taken orally directly. It does not need to be dissolved in water before taking like other calcium supplements, making it more convenient to use. Based on the above advantages, liposomal calcium is a relatively safe and easy-to-absorb calcium supplement, suitable for long-term use, and can meet the body's demand for calcium. According to the recommendations of the World Health Organization, the daily calcium intake for adults should be 1000-1300 mg. In Taiwan, the seventh edition of the revised reference intake of dietary nutrients for Chinese people recommends that the daily intake for adults should be 1,000 mg. The calcium dose used in this study was 500 mg. The purpose was to explore whether the sustained-release characteristics of liposome coating technology can improve the absorption rate after consuming calcium powder and achieve better bioavailability. It is expected that microlipids made by lecithin can Lipid calcium powder increases its maintenance time in the blood, thereby increasing the supplementary effect of calcium, and is an alternative to calcium supplements.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Apr 2024
Shorter than P25 for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 2, 2024
CompletedStudy Start
First participant enrolled
April 8, 2024
CompletedFirst Posted
Study publicly available on registry
April 17, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2024
CompletedApril 17, 2024
April 1, 2024
8 months
April 2, 2024
April 12, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
General examination
BMI(Body Mass Index is a simple calculation using a person's height and weight. The formula is BMI = kg/m2 where kg is a person's weight in kilograms and m2 is their height in metres squared) and blood pressure
Day 14 and 28
Hematology Test
Fasting blood glucose, triglycerides, total cholesterol, Blood urea nitrogen, Creatinine(Blood urea nitrogen (BUN) and creatinine tests can be used together to find the BUN-to-creatinine ratio (BUN:creatinine). A BUN-to-creatinine ratio can help your doctor check for problems, such as dehydration, that may cause abnormal BUN and creatinine levels.), GOT, GPT
Day 14 and 28
Study Arms (2)
Stage 1
OTHERDay 14
Stage 2
OTHERDay 28
Interventions
Number 1-10 :General vitamin C powder group (Contains 1500 mg Ca); Number 11-20: liposomal encapsulation Ca powder group (Contains 1500 mg of Ca and lecithin and is coated)
Number 11-20 :General vitamin C powder group (Contains 1500 mg Ca); Number 1-10: liposomal encapsulation Ca powder group (Contains 1500 mg of Ca and lecithin and is coated)
Eligibility Criteria
You may qualify if:
- Adults aged 20-60 years old, without heart, liver, kidney, endocrine or major organic diseases (patient report), and able to fully cooperate with the experiment.
You may not qualify if:
- Patients with renal insufficiency and dialysis
- Cancer patients
- Underweight (BMI#17) or obese (BMI#27)
- Those taking medications for chronic diseases
- Blood pressure systolic blood pressure # 130 mmHg or diastolic blood pressure # 85 mmHg
- Fasting blood glucose # 100 mg/dL
- Fasting triglycerides # 150 mg/dL, total cholesterol # 200 mg/dL
- Have a history of vitamin C allergy
- People suffering from mental illness
- Pregnant and breastfeeding women
- Patients with hemosiderosis
- Kidney stone patients
- Supplements for those who take calcium for a long time
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
National Yang Ming Chiao Tung University
Taipei, Beitou Dist., 112, Taiwan
National Yang Ming Chiao Tung University
Taipei, 112, Taiwan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant professor
Study Record Dates
First Submitted
April 2, 2024
First Posted
April 17, 2024
Study Start
April 8, 2024
Primary Completion
December 1, 2024
Study Completion
December 1, 2024
Last Updated
April 17, 2024
Record last verified: 2024-04
Data Sharing
- IPD Sharing
- Will not share